First-line Treatment of Metastatic Disease Cisplatin-ineligible Patients

Cathomas Richard; De Santis Maria; Galsky Matthew D.

首页> 外文期刊>Hematology/Oncology Clinics of North America >First-line Treatment of Metastatic Disease Cisplatin-ineligible Patients

【24h】

First-line Treatment of Metastatic Disease Cisplatin-ineligible Patients

机译：不适合转移性顺铂的患者的一线治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

More than 50% of patients with advanced urothelial carcinoma are not eligible for the standard treatment with cisplatin-based chemotherapy. In general, cisplatin-ineligible patients with metastatic urothelial cancer experience poor outcomes with standard treatment, although substantial heterogeneity exists. Baseline variables associated with poor prognosis include borderline performance status, presence of visceral metastases, liver metastases, and low hemoglobin. Although no standard treatment has been defined for cisplatin-ineligible patients, recommendations regarding carboplatin-based combination chemotherapy versus singleagent chemotherapy versus best supportive care are typically based on performance status and renal function. The clinical development of novel agents is of considerable interest.

机译：超过50％的晚期尿路上皮癌患者不符合使用基于顺铂的化学疗法进行标准治疗的资格。通常，尽管存在明显的异质性，但顺铂不适合的转移性尿路上皮癌患者的标准治疗效果较差。与不良预后相关的基线变量包括临界状态，内脏转移，肝转移和低血红蛋白。尽管尚无适合顺铂患者的标准治疗方法，但有关基于卡铂的联合化疗，单药化疗与最佳支持治疗的建议通常是基于患者的状态和肾功能。新药的临床开发引起了极大的兴趣。

著录项

来源
《Hematology/Oncology Clinics of North America》 |2015年第2期|共12页
作者
Cathomas Richard; De Santis Maria; Galsky Matthew D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Urothelial carcinoma; Unfit for cisplatin; Prognostic factors; Carboplatin; Gemcitabine;

机译：尿路上皮癌;不适合顺铂;预后因素;卡铂;吉西他滨;

相似文献

外文文献
中文文献
专利

1. First-line Treatment of Metastatic Disease Cisplatin-ineligible Patients [J] . Cathomas Richard, De Santis Maria, Galsky Matthew D. Hematology/Oncology Clinics of North America . 2015,第2期

机译：不适合转移性顺铂的患者的一线治疗
2. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients - Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer [J] . Irene Resch, Shahrokh F. Shariat, Kilian M. Gust Memo - Magazine of European medical oncology . 2018,第1期

机译：PD-1和PD-L1抑制剂在铂金疗法中或在顺铂型患者中的一线治疗后 - 急剧提高预后和转移性尿路上皮癌患者无望的数十年后的预后和整体生存
3. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study [J] . Balar Arjun V., Castellano Daniel, ODonnell Peter H., The lancet oncology . 2017,第11期

机译：第一线Pembrolizumab在顺铂 - 不合格患者患有局部晚期和不可切除或转移性尿路上皮癌症（Keynote-052）：多期，单臂，第2期研究
4. Is High-Dose Chemotherapy Plus Stem-Cell Transplant the Standard Treatment for Patients Failing First-Line Chemotherapy for Metastatic Germ Cell Tumor? [C] . Christian Kollmannsberger, Lawrence Einhorn, Craig Nichols Genitourinary Cancers Symposium. . 2014

机译：高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗？
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm multicentre phase 2 trial [O] . Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, -1

机译：Atezolizumab作为不适合顺铂治疗的局部晚期和转移性尿路上皮癌患者的一线治疗：一项单臂多中心2期试验
7. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [O] . Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, 2017

机译：atezolizumab作为顺铂型职有患者的一线治疗局部晚期和转移性尿路上皮癌：单臂，多期，第2期试验

First-line Treatment of Metastatic Disease Cisplatin-ineligible Patients

摘要

著录项

相似文献

相关主题

期刊订阅